(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
The most effective method to Pick the Best Material Organization: Insider Tips- 10 Hints for a Fruitful New employee screening
- Pick Your Favored kind of sandwich
- Etymological Investigation Disclosed: A Survey of \Dominating New Tongues\ Language Learning Application
- Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- 25 Most Beautiful Villages in France You Can Actually Visit
- Surveys of Thrillers That Re-imagined the Class
- Ever Wonder What An EV Motorcycle Water Crossing Would Be Like? Here You Go
- 'Senseless violence' erupts at Christmas tree lighting; 4 injured
